MiroBio is a new start-up in the United Kingdom that has, with a fundraising of $34Million, launched itself for the development of therapeutic antibodies. These will assist in the recovery of autoimmune disorders and inflammatory disorders and has been set up based on the discoveries that have been made at the laboratories of Professor Simon Davis, professor of molecular immunology at the MRC Weatherall Institute of Molecular Medicine, and Professor Richard Cornall, Nuffield professor of clinical medicine at Oxford University.
Using more than 15 years of research, they aim to draw the immune-signaling mechanism to the cell surface. The focus is to the develop such antibodies to ‘reapply the natural breaks’ of the immune system, which are faulty as a result of the autoimmune diseases. According to a statement the proceeds will be used by MiroBio to “advance its lead programs, strengthen its proprietary platform, expand its discovery efforts and build out its management team for the next phase of growth”.
MiroBio is the eight start-up that has emerged out of Oxford University in this year and is following the footsteps of other such start-ups which include but are not limited to, GyreOx, antibiotic specialist and Lime Biosciences, a DNA assembly company. Moreover, despite the impact and consequences around the uncertainty of Brexit, the figures published by the BioIndustry Association and Informa Pharma Intelligence support that the life science sector in the United Kingdom is in good health, with substantial amount of fundraising to support the growth of the country.